![](https://monteverdelaw.com/wp-content/uploads/case-logo/adamas-pharmaceuticals-inc.png)
Adamas Pharmaceuticals, Inc. (ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, ADMS shareholders will receive $8.10 plus two contingent value rights collective worth $1.00 in cash per share they own.